CXCR4 and prostate cancer: However, in osteosarcoma and bone-metastatic breast and prostate cancer cells bisphosphonates downregulated CXCR4, which suppressed CXCL12-CXCR4 signaling-induced invasion though this phenomenon needs to be tested in vivo (261–263).